Private biotechs raised a record-breaking $16.8 billion in 2018, blowing past the record $12.1 billion set the previous year.
While most of the top 10 are expected to defend their relative rankings into 2024, ambitious or inspired M&A deals could help companies lower on the list…
2016 was the year of the makeover. The top 10 medtech players are all in varying stages of transformation.
Amid new approvals last year, drugmakers also suffered R&D setbacks, cut research staff, rejigged their operations and refocused their pipelines.